Skip to main content

Advertisement

ADVERTISEMENT

News

BioStem Technologies 

https://mailchi.mp/e189de2ec1fe/zacks-research-initiates-bsem-coverage-and-640-price-target-17980450?e=5eb67cf560

BioStem announced that the Institute Review Board (IRB) approved a clinical study to evaluate the efficacy of AmnioWrap2 (AW2) in patients with DFU. Once BioStem completes the study, the company plans to commercially advance AW2 with expanded Payer Insurance Coverage within the DFU market.

Advertisement

Advertisement

Advertisement